Notably, p53 and KRAS mutations were co‐associated with ASS1‐deficient non‐squamous NSCLC contributing to the poor clinical outcomes; PD‐L1 expression was commonly absent (<1% staining by the 22C3 assay). Here, KRAS is linked to non-small cell lung carcinoma.